[Form 4] Kindly MD, Inc. Insider Trading Activity
Mark W. Yusko, a director of Kindly MD, Inc. (NAKA), reported an acquisition of 112,781 restricted stock units (RSUs) on 09/22/2025. The filing shows these RSUs were granted at a price of $0 and that the reporting person will beneficially own 2,212,781 shares following the grant. The RSUs vest on August 15, 2026 and are subject to the reporting personontinuing service on the companyoard through that vesting date. The Form 4 was signed and submitted by an attorney-in-fact on behalf of the reporting person.
- Director alignment: Grant of 112,781 RSUs aligns the reporting personinancial incentives with long‑term shareholder value
- Increased disclosed ownership: Beneficial ownership rises to 2,212,781 shares, improving transparency of insider holdings
- Not immediately vested: RSUs vest on August 15, 2026 and require continued board service through that date
- Limited disclosure: Filing does not specify total outstanding shares, settlement method for RSUs, or board approval context
Insights
TL;DR: Director received time‑based RSUs that align long‑term incentives with shareholders but vesting requires continued board service.
The grant of 112,781 RSUs to a director is a standard compensation mechanism to align director incentives with shareholder value over time. Because the units vest on a specified future date only if board service continues through August 15, 2026, the award ties retention and long‑term performance to the companyquity. The filing provides clear disclosure of the grant date, grant amount, and vesting condition but does not disclose the rationale for the award or any board approval details; those would appear in proxy or compensation disclosures.
TL;DR: The transaction increases the directoreneficial stake to 2,212,781 shares via time‑vesting RSUs granted at no cash cost.
The Form 4 reports an in‑kind equity award (RSUs) recorded at $0 per unit and increases reported beneficial ownership to 2,212,781 shares. These RSUs are not immediately exercisable and carry a vesting condition tied to continued board service through August 15, 2026, so any market impact depends on future vesting and potential settlement terms. The disclosure is limited to the grant mechanics; no information on dilution, total share count, or expected settlement method is provided in this filing.